CRYSTAL LAKE, Ill. and ORLANDO, Fla. (March 15, 2021) — Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions, and Noble, an Aptar Pharma company, world leader in drug delivery training device programs, today announced their collaboration with dne pharma, a leader in addiction medicine in Northern Europe. Both [...]
“Human Factors Plus” (HF+) is a natural extension of Noble’s deep understanding of the patient experience when it comes to self-administering drug therapies ORLANDO, Fla. (February 2, 2021) – Noble, an Aptar Pharma company and world leader in providing drug delivery training device programs for pharmaceutical companies and original equipment manufacturers, today announces the [...]
The biopharmaceutical industry has experienced incredible exponential growth in recent decades. Annual revenues have increased from US$4.4 billion (£3.4 billion) in 1990 to $275 billion (£213 billion) in 2018 (a 6,250% increase) and now represent more than 25% of the total pharmaceutical market.1 A primary driver of this rapid expansion is the pioneering pursuit [...]
Crystal Lake, Ill. and Orlando, Fla. (October 5, 2020) — Noble and Aptar Pharma are pleased to announce the launch of AdhereIT® — a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT® is the first fully [...]
The Internet of Things (IoT) and connected devices have transformed our everyday lives, from web-connected televisions and smart kitchen appliances to fitness trackers and home security systems. Similarly, connected medical devices are poised to revolutionise healthcare and drug delivery. The medical technology industry designs and manufactures more than 500,000 different types of medical devices [...]
With more biologics and drug delivery device options entering the market in recent years, pharma companies can decide whether it would be easier for patients to self-inject with an autoinjector or prefilled syringe, depending on drug viscosity and other factors. Some biologics also offer patients and their healthcare providers (HCPs) the ability to choose [...]
Nasal drug repurposing has seen a real resurgence recently, driven by several factors. From an economic perspective, partners benefit from reduced development costs, intellectual property (IP) creation, increased market share and extended lifecycle. The regulatory pathways, such as the US 505(b)2, sometimes complemented by orphan drug designation, are faster and less complex. It may [...]
Diagnoses of chronic illnesses such as rheumatoid arthritis (RA), Crohn’s disease and osteoporosis are expected to skyrocket in the coming decade, resulting in growing use of patient-centric drug delivery devices – including autoinjectors, prefilled syringes with safety features, and on-body and respiratory devices. Because of the complexity of injectable treatment regimens, onboarding aids – [...]
In the January 2020 edition of STAT News was a news release from 215 biopharma CEOs and industry leaders. The news release leverages 2020 as the beginning of “the dawn of a golden age of medicine [which] will soon have the ability to treat and cure diseases that have long been untreatable and incurable.” [...]